Itacitinib

Unassigned

New Medicines

Acute graft versus host disease (GvHD) in adults - first-line in combination with standard of care (prednisone/methylprednisolone)

Information

New molecular entity
Incyte
Incyte

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Janus-associated kinase 1 (JAK1) inhibitor
The number of allogeneic bone marrow and stem cell transplants is increasing worldwide. Graft-versus-host disease (GvHD) is a serious complication of this type of transplant. The incidence of acute GvHD varies widely, ranging from 10-80% depending on risk factors [1].
Acute graft versus host disease (GvHD) in adults - first-line in combination with standard of care (prednisone/methylprednisolone)
Oral